Feyyaz ÖZDEMİR1, Özlen BEKTAŞ2, İrfan URUÇ3, Yılmaz BÜLBÜL4, Murat TOPBAŞ5, Halil KAVGACI1, Mustafa YILMAZ6, Fazıl AYDIN1
1Karadeniz Teknik Universitesi, Tıp Fakültesi, Tıbbi Onkoloji Bilim Dalı
2Karadeniz Teknik Universitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı
3Ankara Üniversitesi, Tıp Fakültesi, Tıbbi Onkoloji Bilim Dalı
4Karadeniz Teknik Universitesi, Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı
5Karadeniz Teknik Universitesi, Tıp Fakültesi, Halk Sağlığı Anabilim Dalı
6Karadeniz Teknik Universitesi, Tıp Fakültesi, Hematoloji Bilim Dalı, TRABZON
Keywords: Non-small cell lung cancer, LDH, Survival
The aim of this study was to investigate the effect of pretreatment LDH levels on the prognosis of patients with nonsmall-cell lung cancer. Ninety-six patients who were diagnosed with non-small-cell lung cancer in the departments of medical oncology and chest disease of Karadeniz Technical University and the department of medical oncology of Ankara University and had LDH measurements were included in the study.
Normal LDH level group had significantly better prognosis (12.9 months) compared to high LDH level group (6.5 months) (p=0.0011). In the subgroup analysis of LDH groups, the groups were statistically uniform in age, sex, performance status, stage and preferred treatment modality (surgery, radiotherapy, chemotherapy) parameters.
The poor prognosis, seen in high LDH level group may be due to their resistance to chemotherapy and high recurrence and low remission rates. More comprehensive studies are needed in this area.